Yeah...I know...the "M" word...but clusterheads have had to tag along behind treatments for that FOREVER anyway....

Best

Jon

PS I tried to post in a more friendly form with active links...unable...try FDA.gov (Ajovy)

                       
     The Division of Drug Information (DDI) - serving the public by providing information on human drug products and drug product regulation by FDA
________________________________________
                 
                       
     Today, the US Food and Drug Administration (FDA) approved Ajovy (fremanezumab-vfrm) for the preventive treatment of migraine in adults. Ajovy is the second FDA-approved preventive migraine treatment in a new class of drugs that work by blocking the activity of calcitonin gene-related peptide (CGRP), a molecule that is involved in migraine attacks. Aimovig (erenumab-aooe), the first in this class, was approved on May 17, 2018.

Patients often describe migraine headache pain as an intense pulsing or throbbing pain in one area of the head. Additional symptoms include nausea and/or vomiting and sensitivity to light and sound. Migraine attacks can cause significant pain or hours to days and can be so severe that the pain is disabling. Warning symptoms known as aura may occur before or with the headache. These can include flashes of light, blind spots, or tingling on one side of your face or in your arm or leg.

Ajovy is contraindicated in patients with serious hypersensitivity to fremanezumab-vfrm or to any of the excipients. Hypersensitivity reactions, including rash, pruritis (itching), drug hypersensitivity, and urticaria (hives) were reported with Ajovy in clinical trials. Most reactions were mild to moderate, but some led to discontinuation or required corticosteroid treatment. Most reactions were reported from within hours to one month after administration. The most common adverse reactions were injection site reactions and infections.

For more information, please visit: Ajovy (fremanezumab-vfrm) .

                 
     ________________________________________
This is an automated message delivery system. Replying to this message will not reach DDI staff. If you have comments or questions, please contact us at: 1-888-INFO FDA (1-888-463-6332) or (301) 796-3400 from 8:00 am - 4:30 pm ET Monday - Friday. You can also email us at druginfo@fda.hhs.gov.
•      For additional drug information, please visit the DDI Web page.
•      For up-to-date drug information, follow the FDA’s Division of Drug Information on Twitter: FDA_Drug_Info.
•      This service is provided to you at no charge by the U.S. Food & Drug Administration (FDA).
________________________________________
                 
                       

           
                       


U.S. Food and Drug Administration
10903 New Hampshire Avenue, Silver Spring, MD 20993
1-888-INFO-FDA (1-888-463-6332)
Privacy Policy | Multimedia File Viewing and Clickable Links are available for Registered Members only!!  You need to or
Manage Preferences or Unsubscribe from this List | Unsubscribe from all Email Lists

Aimovig targets the trigeminal headache pathway. Cluster headache is a trigeminal syndrome, migraine is not classically in that pathway but it may be involved. Aimovig works to prevent clusters, in my case.